Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes

Vaccine

Volumn 32, Issue 8, 2014, Pages 931-937

  Gaillard, María Emilia ^a   Bottero, Daniela ^a   Errea, Agustina ^a   Ormazábal, Maximiliano ^a   Zurita, M Eugenia ^a   Moreno, Griselda ^a   Rumbo, Martin ^a   Castuma, Celina ^a   Bartel, Erika ^a   Flores, Dario ^a   van der Ley, Peter ^b   van der Ark, Arno ^b   F Hozbor, Daniela ^a  

^a FACULTAD DE CIENCIAS EXACTAS   (Argentina)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Acellular vaccines; Bordetella pertussis; OMVs; Whooping cough

Indexed keywords

ACELLULAR VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 5; INTERLEUKIN 6; PERTUSSIS TOXIN; PERTUSSIS VACCINE; TETANUS TOXOID;

ACTIVE IMMUNIZATION; ALPHA CHAIN; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL IMMUNITY; BACTERIAL OUTER MEMBRANE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BORDETELLA PERTUSSIS; CLONING; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL ELECTROPHORESIS; GENOTYPE; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOLOGICAL MEMORY; LETHAL DOSE; LIMIT OF DETECTION; MEMBRANE VESICLE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OUTER MEMBRANE VESICLE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TH1 CELL; TH2 CELL; VACCINATION; WEIGHT GAIN; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

ACELLULAR VACCINES; BORDETELLA PERTUSSIS; OMVS; WHOOPING COUGH;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA PERTUSSIS; CROSS PROTECTION; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; GENOTYPE; IMMUNOLOGIC MEMORY; MICE; MICE, INBRED BALB C; PERTUSSIS TOXIN; RECOMBINANT PROTEINS; TH1 CELLS; TH2 CELLS; VACCINES, ACELLULAR; WHOOPING COUGH;

EID: 84893012421     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.12.048     Document Type: Article

References (33)

1. Sato Y., Kimura M., Fukumi H. Development of a pertussis component vaccine in Japan. Lancet 1984, 1:122-126.
2. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996, 334:349-355.
3. Olin P., Rasmussen F., Gustafsson L., Hallander H.O., Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine ad hoc group for the study of pertussis vaccines. Lancet 1997, 350:77-1569.
4. Bart M.J., van Gent M., van der Heide H.G., Boekhorst J., Hermans P., Parkhill J., et al. Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMC Genomics 2010, 11:627.
5. Wendelboe A.M., Van Rie A., Salmaso S., Englund J.A. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005, 24:S58-S61.
6. Witt M.A., Arias L., Katz P.H., Truong E.T., Witt D.J. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis 2013, 56:1248-1254.
7. Mooi F.R., van Loo I.H., van Gent M., He Q., Bart M.J., Heuvelman K.J., et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis 2009, 15:1206-1213.
8. Mooi F.R., VDM N.A., De Melker H.E. Pertussis resurgence: waning immunity and pathogen adaptation-two sides of the same coin. Epidemiol Infect 2013, 1-10.
9. Asensio C.J., Gaillard M.E., Moreno G., Bottero D., Zurita E., Rumbo M., et al. Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. Vaccine 2011, 29:1649-1656.
10. World Health Organization (WHO) Expert committee on biological standardization. WHO/BS/2011.2158 (English only) 2011, 1-64. World Health Organization (WHO).
11. Bottero D., Gaillard M.E., Fingermann M., Weltman G., Fernandez J., Sisti F., et al. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains. Clin Vaccine Immunol 2007, 14:1490-1498.
12. Antoine R., Locht C. Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin. Infect Immun 1990, 58:1518-1526.
13. Geurtsen J., Steeghs L., Hamstra H.J., Ten Hove J., de Haan A., Kuipers B., et al. Expression of the lipopolysaccharide-modifying enzymes PagP and PagL modulates the endotoxic activity of Bordetella pertussis. Infect Immun 2006, 74:5574-5585.
14. Hozbor D., Rodriguez M.E., Fernandez J., Lagares A., Guiso N., Yantorno O. Release of outer membrane vesicles from Bordetella pertussis. Curr Microbiol 1999, 38:273-278.
15. Roberts R., Moreno G., Bottero D., Gaillard M.E., Fingermann M., Graieb A., et al. Outer membrane vesicles as acellular vaccine against pertussis. Vaccine 2008, 26:4639-4646.
16. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
17. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
18. World Health Organization (WHO) Recommendations for whole-cell pertussis vaccine. Annex 6 2007, World Health Organization (WHO).
19. van Loo I.H., van der Heide H.G., Nagelkerke N.J., Verhoef J., Mooi F.R. Temporal trends in the population structure of Bordetella pertussis during 1949-1996 in a highly vaccinated population. J Infect Dis 1999, 179:915-923.
20. Mooi F.R., van Oirschot H., Heuvelman K., van der Heide H.G., Gaastra W., Willems R.J. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun 1998, 66:670-675.
21. van Loo I.H., Heuvelman K.J., King A.J., Mooi F.R. Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J Clin Microbiol 2002, 40:1994-2001.
22. Octavia S., Sintchenko V., Gilbert G.L., Lawrence A., Keil A.D., Hogg G., et al. Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-2010. J Infect Dis 2012, 205:1220-1224.
23. Lam C., Octavia S., Bahrame Z., Sintchenko V., Gilbert G.L., Lan R. Selection and emergence of pertussis toxin promoter ptxP3 allele in the evolution of Bordetella pertussis. Infect Genet Evol 2012, 12:492-495.
24. Advani A., Gustafsson L., Ahren C., Mooi F.R., Hallander H.O. Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs. Vaccine 2011, 29:3438-3442.
25. Hallander H.O., Advani A., Donnelly D., Gustafsson L., Carlsson R.M. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J Clin Microbiol 2005, 43:2856-2865.
26. Mills K.H., Ryan M., Ryan E., Mahon B.P. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 1998, 66:594-602.
27. Bottero D., Gaillard M.E., Basile L.A., Fritz M., Hozbor D.F. Genotypic and phenotypic characterization of Bordetella pertussis strains used in different vaccine formulations in Latin America. J Appl Microbiol 2012, 112:1266-1276.
28. Geurtsen J., Banus H.A., Gremmer E.R., Ferguson H., de la Fonteyne-Blankestijn L.J., Vermeulen J.P., et al. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice. Clin Vaccine Immunol 2007, 14:821-829.
29. Denoel P., Godfroid F., Guiso N., Hallander H., Poolman J. Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model. Vaccine 2005, 23:5333-5341.
30. O'Hagan D.T., MacKichan M.L., Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 2001, 18:69-85.
31. Ross P.J., Sutton C.E., Higgins S., Allen A.C., Walsh K., Misiak A., et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog 2013, 9:e1003264.
32. Mills K.H., Barnard A., Watkins J., Redhead K. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 1993, 61:399-410.
33. Ryan M., Murphy G., Ryan E., Nilsson L., Shackley F., Gothefors L., et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 1998, 93:1-10.